Skip to main content Back to Top
Advertisement

8/24/2019

Potassium Phosphate Injection

Reason for the Shortage

    • American Regent has not had potassium phosphate injection available since 2012. It is unclear if and when product will return to market.
    • Fresenius Kabi had potassium phosphate injection on shortage due to increased demand.
    • Pfizer had potassium phosphate injection on shortage due to manufacturing delays.

Available Products

    • Potassium Phosphate injection, Fresenius Kabi, 3 mmol/mL, 15 mL vial, 25 count, NDC 63323-0086-15
    • Potassium Phosphate injection, Fresenius Kabi, 3 mmol/mL, 5 mL vial, 25 count, NDC 63323-0086-05
    • Potassium Phosphate injection, Fresenius Kabi, 3 mmol/mL, 50 mL vial, 25 count, NDC 63323-0086-50
    • Potassium Phosphate injection, Pfizer, 3 mmol/mL, 15 mL vial, 25 count, NDC 00409-7295-01
    • Glycophos injection, Fresenius Kabi, 1 mmol/mL, 20 mL vial, 10 count, NDC 63323-0241-20

Estimated Resupply Dates

    • All marketed presentations are available.

Safety

    • Pfizer has issued a recall on 7 lots of potassium phosphate 3 mmol/mL 15 mL vials due to sterility concerns. https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm563382.htm

Alternative Agents & Management

    • In cooperation with FDA, Fresenius Kabi USA is providing Glycophos (sodium glycerophosphate) injection to the US market to help alleviate the shortage of phosphate injections. Glycophos is manufactured in an FDA-approved facility in Norway by Fresenius Kabi AG. Details can be found on https://www.fda.gov/downloads/drugs/drugsafety/drugshortages/ucm591758.pdf

Updated

Updated August 24, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 31, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins